US pharmaceutical services provider Petauri announced on Tuesday that it has established Petauri Advance, a medical communications platform.

The new platform is designed to integrate and optimise healthcare communications for the life sciences industry, bridging the gap between healthcare professionals, biopharmaceutical and diagnostic innovators, and patients. It provides a wide range of specialised services to support the diverse requirements of the healthcare sector, including: KOL engagement strategy and implementation; insight generation strategy and executing those insights into action; commercial development strategy, launch planning and mapping; scientific communications and disease awareness; abstracts, publications and trial education; MSL training and engagement materials; conference and congress strategy, support and competitive intelligence; promotional and non-promotional content; and digital strategy, implementation and analytics.

Petauri Advance brings together the agencies acquired by Petauri in 2024: Blendworks, Bluprint Oncology, Cogency, DRIVE, MOMENTUM, PROPEL and Verascity Science.

Jan Hannon, group president, said: "We can now offer our clients scientific communications and therapeutic acumen across multiple therapeutic areas. Our goal for Petauri Advance is to clarify complex science for those on the frontlines of care delivery to improve patient outcomes."